BMJ  2007;334:376 (24 February), doi:10.1136/bmj.39128.449317.BE

Editorials

Prescribing oral chemotherapy

Standardised dosing can improve the safety of prescribing

The use of oral anticancer agents for the treatment of common malignancies has increased over the past few years. Of about 300 new anticancer agents in development, 20-25% are oral products.¹ Many novel "target agents" such as inhibitors of the epidermal growth factor receptor (for example, erlotinib) and the vascular endothelial growth factor receptors (for example, sunitinib and sorafenib) are given orally. Patients prefer oral agents because they are more convenient, allow greater autonomy, and avoid venepuncture and the associated risks of indwelling venous catheters.²

Despite the advantages of oral anticancer agents, they do pose challenges such as poor compliance, a small but definite risk of unintentional overdose, and a greater risk of drug-drug and drug-food interactions.³ In this week's BMJ, Weingart and colleagues evaluate the safety practices of 62 National Cancer Institute designated centres in the United States with regard to prescribing oral chemotherapy.⁴ Such institutions would be expected to have high safety standards, but the survey found that few of the safeguards suggested for parenteral anticancer drugs were used for oral agents given in an ambulatory setting. More than half of the responding centres (23 of 42) had no required element for oral chemotherapy prescriptions; these included the diagnosis, protocol number, cycle number on the prescription, or a double check of the prescription by a second clinician.⁴

Since 1996, most US hospitals have devised programmes for the safe delivery of oral and parenteral chemotherapy.⁵ Recommendations emphasise the need for a comprehensive, interdisciplinary approach to reduce the number of errors whereby the accuracy of chemotherapy prescriptions must be verified by a system of double checking.⁶⁷ Weingart and colleagues' survey suggests that these safety recommendations often assume chemotherapy agents will be administered in a monitored, clinical environment, and not in an ambulatory setting. Oral anticancer agents given outside a healthcare centre require the same safeguards as parenteral agents, unless the dosing regimen of oral agents can be simplified.

One source of prescribing error stems from the unique practice in oncology of calculating doses on the basis of the patient's body surface area (calculated from height and weight). This practice has been repeatedly questioned in recent years, and the evidence to support it is limited.⁸⁹¹⁰

The rationale for using body surface area to calculate drug doses is even less clear for oral agents than for parenteral ones, as pharmacokinetic variability between patients is greater for oral agents and less likely to be associated with body size.¹¹¹² Thus, calculating the dose of oral anticancer agents on this basis is unlikely to improve safety and may even increase the risk of underdosage or overdosage. Some drug companies have responded to these risks by creating standard starting doses for all patients. However, some widely used oral agents (such as capecitabine) still require dosing on the basis of body surface area.¹³

For doses based on body surface area, safety standards should be the same as for parenteral therapy—the prescription should include the patient's height, weight, and body surface area; dose per body surface area; final calculated dose; and total number of doses per treatment course. Dosing calculations should be verified by a multidisciplinary system of double checking.⁶⁷⁸

Prescriptions for agents with standardised dosing may not need these elaborate safety measures as the risks of the prescriber making a dosing error or the patient making an error when taking the drug are much lower.

The use of oral anticancer agents will continue to increase as more agents come on to the market. We suggest standardising oral anticancer doses in an effort to eliminate unnecessary dosing complexity and thereby improve patient safety.

Department of Medicine, Section of Haematology/Oncology, University of Chicago, Chicago, Illinois 60637, USA

---

Competing interests: None declared.

Provenance and peer review: Commissioned; not externally peer reviewed.

References

1. Birner A. Safe administration of oral chemotherapy. Clin J Oncol Nurs 2003;7:158-62.[Medline]
2. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-5.[Abstract/Free Full Text]
3. Skirvin JA, Lichtman SM. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging . 2002;19:25-42[CrossRef][ISI][Medline]
4. Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 2007 doi: 10.1136/bmj.39069.489757.55[Abstract/Free Full Text]
5. Fischer DS, Alfano S, Knobf MT, Donovan C, Beaulieu N. Improving the cancer chemotherapy use process. J Clin Oncol 1996;14:3148-55.[Abstract]
6. ASHP guidelines on preventing medication errors with antineoplastic agents. Am J Health Syst Pharm 2002;59:1648-68.[Free Full Text]
7. Womer RB, Tracy E, Soo-Hoo W, Bickert B, DiTaranto S, Barnsteiner JH. Multidisciplinary systems approach to chemotherapy safety: rebuilding processes and holding the gains. J Clin Oncol 2002;20:4705-12.[Abstract/Free Full Text]
8. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19:171-7.[CrossRef][ISI][Medline]
9. Newell DR. Getting the right dose in cancer chemotherapy—time to stop using surface area? Br J Cancer 2002;86:1207-8.[CrossRef][ISI][Medline]
10. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-8.[Abstract/Free Full Text]
11. Hande K, Messenger M, Wagner J, Krozely M, Kaul S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 1999;5:2742-7.[Abstract/Free Full Text]
12. McLeod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 1999;5:2669-71.[Free Full Text]
13. Ratain MJ. Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol 2002;20:1434-5.[Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Oral chemotherapy safety practices at US cancer centres: questionnaire survey

Saul N Weingart, Jonathan Flug, Daniela Brouillard, Laurinda Morway, Ann Partridge, Sylvia Bartel, Lawrence N Shulman, and Maureen Connor
BMJ 2007 334: 407. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Ratain, M. J., Cohen, E. E. (2007). The Value Meal: How to Save $1,700 Per Month or More on Lapatinib. JCO 25: 3397-3398 [Full text]